ULIHF Stock Chart & Stats
$1.88
$0.10(8.70%)
At close: 4:00 PM EDT
$1.88
$0.10(8.70%)
Day’s Range― - ―
52-Week Range$1.10 - $2.45
Previous CloseN/A
Volume13.00K
Average Volume (3M)0.00
Market Cap
$2.33B
Enterprise Value$7.94B
Total Cash (Recent Filing)$11.24B
Total Debt (Recent Filing)$4.99B
Price to Earnings (P/E)7.3
Beta-0.30
Next Earnings
Aug 27, 2026EPS Estimate
0.06Next Dividend Ex-DateN/A
Dividend Yield2.82%
Share Statistics
EPS (TTM)1.14
Shares Outstanding1,970,276,500
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.39
Price to Book (P/B)1.13
Price to Sales (P/S)1.49
P/FCF Ratio22.94
Enterprise Value/Market Cap3.41
Enterprise Value/Revenue0.60
Enterprise Value/Gross Profit1.44
Enterprise Value/Ebitda2.81
Forecast
1Y Price Target
$1.98Price Target Upside5.57% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)0.08
Revenue Forecast (FY)$1.63B
Bulls Say, Bears Say
Bulls Say
Cost ManagementSelling costs were reduced by Rmb260mn to Rmb715mn, showing a significant year-over-year decrease.
Growth ProjectionsFurther growth is expected from finished drugs, including the soon-to-be-approved liraglutide generic, insulins, and animal drugs.
Product LaunchesAnimal drugs are on a strong growth track with new product launches.
Bears Say
Capacity ConcernsManagement does not see extra capacity coming online to pressure 6-APA prices, which might limit future supply flexibility.
Market ExpectationsStreet's estimate has already moved up by 6% since early July, suggesting expectations may be high and challenging to exceed.
Profit Outlook1H24 net profit was in line with estimates, but only slightly above consensus, indicating limited upside surprise.
The United Laboratories International Holdings News
ULIHF FAQ
What was The United Laboratories International Holdings Limited’s price range in the past 12 months?
The United Laboratories International Holdings Limited lowest stock price was $1.10 and its highest was $2.45 in the past 12 months.
What is The United Laboratories International Holdings Limited’s market cap?
The United Laboratories International Holdings Limited’s market cap is $2.33B.
When is The United Laboratories International Holdings Limited’s upcoming earnings report date?
The United Laboratories International Holdings Limited’s upcoming earnings report date is Aug 27, 2026 which is in 48 days.
How were The United Laboratories International Holdings Limited’s earnings last quarter?
The United Laboratories International Holdings Limited released its earnings results on Mar 24, 2026. The company reported $0.016 earnings per share for the quarter, beating the consensus estimate of $0.009 by $0.007.
Is The United Laboratories International Holdings Limited overvalued?
According to Wall Street analysts The United Laboratories International Holdings Limited’s price is currently Undervalued.
Does The United Laboratories International Holdings Limited pay dividends?
The United Laboratories International Holdings Limited pays a Quarterly dividend of $0.038 which represents an annual dividend yield of 2.82%. See more information on The United Laboratories International Holdings Limited dividends here
What is The United Laboratories International Holdings Limited’s EPS estimate?
The United Laboratories International Holdings Limited’s EPS estimate is 0.06.
How many shares outstanding does The United Laboratories International Holdings Limited have?
The United Laboratories International Holdings Limited has 1,970,276,500 shares outstanding.
What happened to The United Laboratories International Holdings Limited’s price movement after its last earnings report?
The United Laboratories International Holdings Limited reported an EPS of $0.016 in its last earnings report, beating expectations of $0.009. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of The United Laboratories International Holdings Limited?
Currently, no hedge funds are holding shares in ULIHF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
The United Laboratories International Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
34.89%
12-Months-Change
Fundamentals
Return on Equity
12.65%
Trailing 12-Months
Asset Growth
24.94%
Trailing 12-Months
Company Description
The United Laboratories International Holdings Limited
The United Laboratories International Holdings Limited functions as an investment holding company with a primary focus on the pharmaceutical sector. Its multifaceted operations cover the entire lifecycle of drug development and commercialization, from pioneering research and development to manufacturing, distribution, and sales. The company structures its diverse business into three core divisions: Bulk Medicine, Intermediate Products, and Finished Goods. Its broad product portfolio features a variety of medications, such as oral antibiotics, injectable antimicrobials, cold and cough remedies, ophthalmic solutions, antiviral and anti-hepatitis B drugs, diabetes treatments, topical dermatological preparations, cardiovascular and neurological pharmaceuticals, vitamins, and empty gelatin capsules, alongside active pharmaceutical ingredients (APIs) and other intermediary compounds. Furthermore, the company manufactures and markets soft capsule shells, holds trademarks, engages in pharmaceutical trading, and provides management services. Founded in 1990 and headquartered in Yuen Long, Hong Kong, the firm maintains a significant global reach, conducting business throughout the People's Republic of China, Europe, India, the Middle East, South America, other Asian territories, and internationally.
The United Laboratories International Holdings (ULIHF) Earnings & Revenues
ULIHF Stock 12 Month Forecast
Average Price Target
$1.98
▲(5.57% Upside)
Technical Analysis
China Medical System Holdings
―
Livzon Pharmaceutical Group
―
China Resources Pharmaceutical Group Ltd.
―
Consun Pharmaceutical Group Ltd.
―
Grand Pharmaceutical Group Limited
―
Ownership Overview
―
Insiders
3.51% Mutual Funds
0.08% Other Institutional Investors
92.97% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---